Journal of Rheumatic Diseases最新文献

{"title":"A Challenging Target: Persistent Pain During the Remission State in Rheumatoid Arthritis Patients.","authors":"Doo-Ho Lim","doi":"10.4078/jrd.22.0047","DOIUrl":"https://doi.org/10.4078/jrd.22.0047","url":null,"abstract":"www.jrd.or.kr Pain is an important symptom in patients with rheumatoid arthritis (RA) and can cause various physical and psychological impairments [1]. Despite recent advances in disease-modifying anti-rheumatic drugs (DMARDs) and the treat-to-target approaches for improved management of inflammation, rheumatologists often encounter patients in the clinic with complaints of moderate to severe pain [2]. In this point, a study by Kim et al. [3] reported in the previous issue of the Journal of Rheumatic Diseases provides important implications of using a multidimensional approach to pain management in RA patients. Pain in RA patients is caused due to several underlying mechanisms. In addition to the inflammatory pain caused by local and systemic cytokine effects, arthritis pain results from simple mechanical stimulations such as weight-bearing and joint movement (nociceptive pain). Changes in the articular environment due to structural joint damage and chronic inflammation can increase neuronal innervation or sensitize peripheral nociceptors at the joint site (peripheral pain sensitization) [4]. Recent studies using functional magnetic resonance imaging have shown increased and modulated cortical responses to pain stimuli in the central nervous system, suggesting a role of central processing in RA-associated pain (central pain sensitization) [5,6]. Moreover, RA patients have a higher prevalence of mood disorders including depression and anxiety compared to healthy individuals, and the psychological distress has been associated with increased levels of pain [7]. The pain characteristics described in RA patients may include symptoms such as aches, shooting or sharp pain, among others, which may be temporary, constant, or weight bearingrelated [8]. An appropriate description of pain obtained from the clinical history and physical examination may aid in elucidation of each pain mechanism underlying RA, or indicate the mechanisms triggered by separate comorbid conditions, including osteoarthritis, fibromyalgia, carpal tunnel syndrome, and depression. Imaging plays a supportive role in measuring disease activity of RA and detecting comorbidities [9]. Plain radiography can detect osteopenia, joint space narrowing, erosion, and osteophytes; however, it is not sensitive so to be better at diagnosing late-stage disease. In recent years, musculoskeletal ultrasonography has emerged as an imaging modality for measuring disease states in RA and osteoarthritis with greater sensitivity and specificity compared to plain radiography. A negative result obtained by musculoskeletal ultrasonography may also be suggestive of other etiologies of pain including fibromyalgia. Persistent or residual pain accompanying an inflammatory remission state is one of the most significant unmet needs in RA patients. In a previous study, Lee et al. [10] mentioned that approximately 47 percent of RA patients with low levels of inflammation reported moderate to high levels of pain, and th","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"30 1","pages":"1-2"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/12/f1/jrd-30-1-1.PMC10351353.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9928883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Treatment of Systemic Sclerosis in Korea.","authors":"Seung-Geun Lee, Ki Won Moon","doi":"10.4078/jrd.22.0029","DOIUrl":"10.4078/jrd.22.0029","url":null,"abstract":"<p><p>Systemic sclerosis (SSc), a rare, chronic progressive systemic autoimmune disease of unknown etiology, is characterized by autoimmunity, tissue fibrosis, and obliterative vasculopathy. SSc can affect all major organs including the skin, blood vessels, lung, heart, kidneys, and gastrointestinal tract. Our understanding of its pathogenesis has increased over the past few decades, leading to improved diagnosis and treatment. However, the mortality rate of SSc remains considerable, mainly due to cardiopulmonary causes. A growing body of evidence suggests that geographical, regional, and ethnic differences could affect the epidemiology, clinical characteristics and prognosis of SSc. Although Korean data of this issue are lacking, a considerable amount of research has been published by many Korean researchers. To establish treatment strategies for Korean patients, extensive Korean research data are needed. This review summarizes the prevalence, incidence, mortality, and clinical and laboratory manifestations of Korean patients with SSc and discusses the current trends in evidence-based treatment and recommendations.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"200-214"},"PeriodicalIF":2.2,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/43/jrd-29-4-200.PMC10351407.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9850315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenosine Deaminase 2 Deficiency Caused by Biallele Variants Including Splicing Variant: The First Case in Korea.","authors":"Sun Cho,&nbsp;Seongyeol Park,&nbsp;Jeong Seok Lee,&nbsp;Young Seok Ju,&nbsp;Yun Jung Choi,&nbsp;Soyoung Lee","doi":"10.4078/jrd.21.0046","DOIUrl":"https://doi.org/10.4078/jrd.21.0046","url":null,"abstract":"<p><p>Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease caused by pathogenic variants of the <i>ADA2</i> gene and has similar clinical features to polyarteritis nodosa (PAN). We, herein, report a case of DADA2 in Korea that was diagnosed in a patient with childhood-onset PAN. The patient had a truncal ataxia and facial palsy caused by thalamic infarction at 34 months of age. Livedo reticularis with Raynaud phenomenon and abdominal pain with fever were followed. Radiologic examination showed multiple infarctions in brain and kidney. She was diagnosed with PAN using skin biopsy and angiography. She had severe hemorrhagic strokes despite medical treatments. Her disease activity was controlled after adding a tumor necrosis factor-α inhibitor. Molecular analysis revealed compound heterozygous pathogenic variants of <i>ADA2</i> gene. This is the first case of DADA2 in Korea. Genetic analysis for <i>ADA2</i> gene should be considered in patients with childhood-onset PAN.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"254-260"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/80/jrd-29-4-254.PMC10351412.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9848122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Epidemiology and Treatment of Ankylosing Spondylitis in Korea.","authors":"Seong-Ryul Kwon,&nbsp;Tae-Hwan Kim,&nbsp;Tae-Jong Kim,&nbsp;Won Park,&nbsp;Seung Cheol Shim","doi":"10.4078/jrd.22.0023","DOIUrl":"https://doi.org/10.4078/jrd.22.0023","url":null,"abstract":"<p><p>Ankylosing spondylitis is a chronic inflammatory disorder characterized by inflammation of the axial skeleton and sacroiliac joints and to a lesser extent by peripheral arthritis and the involvement of some extra-articular organs. It is paramount for the provision of effective health care delivery to be familiar with the epidemiologic studies on prevalence, mortality, and disability. Furthermore, there is no systematic arrangement of studies related to the treatment of ankylosing spondylitis in Korea. In this review, we addressed Korean ankylosing spondylitis epidemiological studies related to prevalence, genetic factor especially human leucocyte antigen-B27, extra-articular manifestations, infections, mortality, radiologic progression, child-birth, and quality of life. Furthermore, we reviewed Korean ankylosing spondylitis treatment researches about treatment trend, patients' registration program called The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry project, biologics and biosimiliars, complications especially infections, and issues about bony progression. There would be value to further studying the epidemiology and treatment of Korean ankylosing spondylitis.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"193-199"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/76/jrd-29-4-193.PMC10351411.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10232915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial Inflammation in the ISN/RPS 2018 Classification of Lupus Nephritis Predicts Renal Outcomes and is Associated With Bcl-2 Expression.","authors":"Sang Jin Lee,&nbsp;Eon Jeong Nam,&nbsp;Man Hoon Han,&nbsp;Yong Jin Kim","doi":"10.4078/jrd.22.0011","DOIUrl":"https://doi.org/10.4078/jrd.22.0011","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the histopathological characteristics of patients with lupus nephritis in the 2018 revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification and assess the prognostic factors.</p><p><strong>Methods: </strong>This study enrolled 92 patients with lupus nephritis, who had conventional treatment and renal biopsy. Each renal tissue was evaluated according to 2018 ISN/RPS classification, and quantified apoptotic regulator protein, the B-cell lymphoma-2 protein (Bcl-2), expressions in selected lymphocyte subsets were measured using novel computational approaches using multicolor confocal images. Histopathological characteristics and prognostic factors of end-stage renal disease (ESRD) and chronic kidney disease (CKD) were compared. Follow-up data were obtained, and survival analysis was conducted.</p><p><strong>Results: </strong>During follow-up period (average 74.3 months), 16 and 18 patients progressed ESRD and CKD, respectively. Multivariable analysis of age, sex, disease activity and pathological features in ISN/RPS demonstrated the extent of interstitial inflammation (grade 0~3) was significantly associated with both ESRD and CKD. When interstitial inflammation was divided into mild (grade 0, 1) and severe (grade 2, 3), Cox regression analysis showed that patients with severe interstitial inflammation were significantly increased risk of both ESRD and CKD (hazard ratio 4.67 and 3.8, respectively). Bcl-2 expression in CD4+ and CD20 cells was significantly higher in the severe interstitial inflammation group compared to in mild interstitial inflammation patients (p=0.006 and 0.010, respectively).</p><p><strong>Conclusion: </strong>The extent of interstitial inflammation can predict clinical renal outcomes. Significantly elevated Bcl-2 expression in both CD4+ and CD20 cells was found in severe interstitial inflammation compared with mild interstitial inflammation.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"232-242"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/d2/jrd-29-4-232.PMC10351406.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of Persistent Pain in Patients With Rheumatoid Arthritis Despite Remission Status: Data From the KOBIO Registry.","authors":"Hyoun-Ah Kim,&nbsp;So Young Park,&nbsp;Kichul Shin","doi":"10.4078/jrd.22.0005","DOIUrl":"https://doi.org/10.4078/jrd.22.0005","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the prevalence of pain in patients with RA in clinical remission and analyze the demographic and clinical characteristics of those who experienced persistent pain despite remission status.</p><p><strong>Methods: </strong>Data from 1,891 patients with RA registered on the Korean College of Rheumatology Biologics and Targeted Therapy registry were obtained. Remission was defined as a Disease Activity Score of 28 joints-erythrocyte sedimentation rate (ESR) <2.6. Pain intensity was classified as severe (pain visual analog scale [VAS] ≥7), moderate (4≤VAS<7), or mild (VAS <4).</p><p><strong>Results: </strong>Our analysis showed that 52.6% of patients complained of severe pain at the start of or during switching biological disease-modifying anti-rheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). Despite having a 36.0% (n=680) remission rate after the use of bDMARDs or tsDMARDs at their 1-year follow-up, 21.5% (n=146) of these patients had moderate-to-severe pain, higher frequency of foot erosions, and comorbidities, such as mental illness, endocrine, renal, and neurological disorders, than patients with a milder degree of pain. The multivariable regression analysis showed that presence of foot erosions, neurological disorders, and use of corticosteroids were independently associated with moderate-to-severe pain in patients with RA despite being in remission. The level of ESR and use of Janus kinase inhibitors were inversely associated with moderate-to-severe pain.</p><p><strong>Conclusion: </strong>Persistent pain and discomfort continue to be a problem for patients with RA in clinical remission. Continued research on insistent pain in patients with RA is warranted to better alleviate distress and improve the quality of life in patients.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"215-222"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/07/jrd-29-4-215.PMC10351409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9928875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?","authors":"Chan Hong Jeon","doi":"10.4078/jrd.22.0034","DOIUrl":"https://doi.org/10.4078/jrd.22.0034","url":null,"abstract":"www.jrd.or.kr Patients with rheumatoid arthritis (RA) tend to have more comorbidities than the general population, but remain at risk of insufficient rheumatological care despite high disease burden and poor outcomes [1]. As life expectancy increases, rheumatologists have more opportunities to see patients with co-morbidities. Although malignancy is a frequent cause of morbidity and mortality, information on the management of RA in patients with malignancy is scarce. In this respect, the study that Joo et al. [2] published in the previous issue of Journal of Rheumatic Diseases provides valuable information on current practice among such patients, suggesting the unmet clinical needs of this population. According to a recent meta-analysis that investigated the pooled data from previous cohort studies, the overall risk of developing malignancy is slightly increased in RA patients. Regarding site-specific risk, the risk of lymphoma and lung cancer was particularly increased [3,4], and it is postulated that a shared etiology such as smoking [5,6] or chronic persistent immune activation may play a role in the development of neoplasms [7,8]. Apart from the inherent risk of malignancy in RA patients, there have been concerns regarding the influence of diseasemodifying antirheumatic drugs (DMARDs) on the risk of developing malignancy. There is conflicting evidence about the relationship between TNF-α inhibitors (TNFis) and malignancy risk; some meta-analyses and patient registry studies have shown that the risk of malignancy is not increased in patients receiving TNFis, whereas other studies have reported increased risk of nonmelanoma skin cancer [9]. Non-TNFi biologics were not linked with increased risk of malignancy in some claimsbased studies and registry data [10,11]. As for new target synthetic DMARDs, Janus kinase inhibitors showed no effect on the overall incidence of malignancy from the general population or those taking biologic DMARDs, although the ageand sexmatched standard incidence ratio of lymphoma was higher than that of the general population [12]. Despite a few reports of increased malignancy risk related to cyclosporin and azathioprine, conventional synthetic DMARDs are generally considered not to increase malignancy risk [13]. There also are some theoretic concerns that concurrent DMARDs might suppress the immune system, thus increasing the risk of malignancy recurrence. However, recent meta-analyses of observational studies showed that the recurrence rate of malignancy in patients who are on DMARDs was not different from that in patients without DMARDs [14]. Drawing firm conclusions about the effects of DMARDs on malignancy risk is challenging. The data provided by randomized controlled studies (RCTs) regarding the risk of malignancy with DMARDs are quite limited; a history of prior malignancy is usually an exclusion criterion of those studies, and considering the long latency of malignancy, RCTs generally do not involve sufficient fo","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"191-192"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/cf/jrd-29-4-191.PMC10351408.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9928876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Tuberculous Myositis: A Systematic Review and Multicenter Cases.","authors":"Ji Hyoun Kim,&nbsp;Jeong Seok Lee,&nbsp;Byoong Yong Choi,&nbsp;Yun-Hong Cheon,&nbsp;Su-Jin Yoo,&nbsp;Ji Hyeon Ju,&nbsp;Kichul Shin,&nbsp;Eu Suk Kim,&nbsp;Han Joo Baek,&nbsp;Won Park,&nbsp;Yeong Wook Song,&nbsp;Woi-Hyun Hong,&nbsp;Yun Jong Lee","doi":"10.4078/jrd.22.0014","DOIUrl":"https://doi.org/10.4078/jrd.22.0014","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and associated underlying conditions of isolated tuberculous myositis (ITBM), a rare extrapulmonary tuberculosis (TB).</p><p><strong>Methods: </strong>A systematic literature search and a multicenter survey were performed using a triangulation strategy. Data from the identified ITBM cases were extracted and analyzed to determine the underlying conditions, clinical presentations, treatments, and outcomes.</p><p><strong>Results: </strong>Based on the systematic review, we identified 58 ITBM, including 9 pediatric, cases in the literature published from 1981 to 2021 25 (43.1%) immunocompromised and 33 (56.9%) non-immunocompromised patients. Immunocompromised cases had a significant shorter symptom duration (median 30.0 vs. 75.0 days) and a higher prevalence of multilocular involvement (20.8% vs. 0%). Among 24 immunocompromised adult patients, dermatomyositis/polymyositis (DM/PM; n=10, 41.7%) were the most common underlying diseases in adults with ITBM identified in the systematic review. Over the past 20 years, 11 Korean adults with ITBM were identified in the multicenter survey. Of 7 immunocompromised cases, two (28.6%) were DM/PM patients. TB death rate of immunocompromised patients was 0.0% and 5/23 (21.7%) in the pediatric and adult ITBM cases identified in the systematic review, respectively, and 3/7 (42.9%) in survey-identified ITBM cases.</p><p><strong>Conclusion: </strong>ITBM has a unique clinical presentation including fever, tenderness, local swelling, overlying erythema, abscess formation and was associated with a grave outcome, especially in immunocompromised hosts. DM/PM was a highly prevalent underlying disease in both systematic review-identified and survey-identified immunocompromised ITBM patients.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"243-253"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/ba/jrd-29-4-243.PMC10351410.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Renal Response in Lupus Nephritis: A Single-center Prospective Cohort Study.","authors":"Dae Jin Park,&nbsp;Young Bin Joo,&nbsp;So-Young Bang,&nbsp;Jiyoung Lee,&nbsp;Hye-Soon Lee,&nbsp;Sang-Cheol Bae","doi":"10.4078/jrd.22.0006","DOIUrl":"https://doi.org/10.4078/jrd.22.0006","url":null,"abstract":"<p><strong>Objective: </strong>To identify the predictive factors for renal response in patients with lupus nephritis (LN).</p><p><strong>Methods: </strong>Patients and data were extracted from a prospective systemic lupus erythematosus cohort in Korea, in which clinical data were collected at 0, 3, 6, and 12 months after induction therapy. Treatment response of LN were evaluated as a complete response (CR), partial response (PR), or non-response (NR) at 3, 6, and 12 months, respectively. Predictive factors for CR at 6 months were evaluated using multivariable Poisson regression analysis.</p><p><strong>Results: </strong>A total of 75 patients with LN who underwent biopsy was enrolled. The mean age at diagnosis of LN was 28.9±9.7 years, and 68 (90.7%) were female. The frequencies of classes III, IV, III+V, IV+V, and V were 20.0%, 44.0%, 16.0%, 12.0%, and 8.0%, respectively. Compared to relapsed LN, new-onset LN showed a lower percentage of glomerulosclerosis (45.5% vs. 76.2%, p=0.013). The overall proportions of CR, PR, and NR at 6 and 12 months were 52.0%, 26.7%, 21.3% and 50.7%, 24.0%, 25.3%, respectively. In multivariate analysis, age at enrollment (odds ratio [OR]=1.02, p=0.022), relapsed LN (OR=0.71, p=0.037), anti-Ro antibody (OR=0.67, p=0.014), and class III LN (OR=1.48, p=0.001) were associated with CR at 6 months.</p><p><strong>Conclusion: </strong>In our prospective cohort, class III LN was a good predictive factor for CR at 6 months in patients with LN, whereas younger age, relapsed LN, and anti-Ro antibody were poor predictive factors.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 4","pages":"223-231"},"PeriodicalIF":2.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/39/jrd-29-4-223.PMC10351413.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Sarcoidosis Misdiagnosed as Hepatosplenic Abscesses: A Case Report and Review.","authors":"Su Min Lee,&nbsp;Hyungwook Choi,&nbsp;Sungmin Lim,&nbsp;Jehee Shin,&nbsp;Ji-Man Kang,&nbsp;Jong Gyun Ahn","doi":"10.4078/jrd.2022.29.3.181","DOIUrl":"10.4078/jrd.2022.29.3.181","url":null,"abstract":"<p><p>Sarcoidosis is a systemic granulomatous disorder of unknown etiology characterized by granuloma formation. Due to the limited incidence of sarcoidosis in pediatric patients, little is known about the clinical course of this disease. A combination of clinical, radiologic, and pathologic examination is necessary to exclude other differential diagnoses (i.e., infection and granulomatous inflammatory disorder) and establish a diagnosis of sarcoidosis. Here, we report a case of histologically confirmed sarcoidosis initially misdiagnosed as hepatosplenic abscesses in an 11-year-old male. Treatment with corticosteroids improved his symptoms and resolved his skin and hepatosplenic lesions. A three-year follow-up was uneventful. This study emphasizes the importance of considering sarcoidosis in children presenting with findings of multi-organ involvement in the presence of histologic evidence of granuloma.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"29 3","pages":"181-186"},"PeriodicalIF":2.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/a7/jrd-29-3-181.PMC10324926.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9904352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}